Medicare will pay hospitals close to its standard mark-up rate for administering cell therapy Yescarta for cancer outpatients, who will have a co-payment of nearly $80,000.
A continuing medical education session at the Society of Gynecologic Oncology’s 2018 Annual Meeting on Women’s Cancer offered insight for optimal selection and administration of PARP inhibitors, as well as homologous recombination deficiency testing in ovarian cancer.

By Will Boggs MD

NEW YORK (Reuters Health) - Outcomes in patients with localized renal masses are favorable in those who choose active surveillance over immediate surgery, according to a database study.

From 2007 to 2014, funding from the National Cancer Institute for ovarian and uterine cancers fluctuated by what percentage?

By David Douglas

NEW YORK (Reuters Health) - Men with germline mutations in the BRCA1 and BRCA2 genes are at increased cancer risk and may benefit from wider screening than is currently done, according to Israeli researchers.

The international workshop on CLL updated the prognostic criteria for their consensus guideline to include all of the following EXCEPT mutational status in which gene?
Rebecca Kirch, JD, executive vice president, Healthcare Quality & Value, National Patient Advocate Foundation, explains the value of palliative care in the context of the triple aim.
Will payers push for services to be provided on an outpatient basis, thus placing financial burden upon the patient, or will they allow the oncologist or facility to use their discretion as to where the infusion will take place?
A new study compared medical care cost estimates of different cancer types for patients aged at least 18 years and provided important evidence about the cost of cancer care across the age spectrum.
The National Comprehensive Cancer Network has issued updates to the primary and second-line therapy options for the treatment of Hodgkin lymphoma.